LOGIN  |  REGISTER
Cue Biopharma

EDAP TMS (NASDAQ: EDAP) Stock Quote

Last Trade: US$6.01 -0.03 -0.50
Volume: 15,831
5-Day Change: -1.15%
YTD Change: 13.83%
Market Cap: US$221.950M

Latest News From EDAP TMS

60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal... Read More
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, announced today preliminary Focal One placement results for the fourth quarter of calendar year 2023. The Company experienced robust demand for its Focal One robotic HIFU technology, placing twelve... Read More
LYON, France, January 2, 2024 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments are effective as of January 1, 2024. “Over the past year, we have continued to align our organization in support of our... Read More
Represents Key Milestone Toward Universal Coverage for Focal One HIFU in France LYON, France, December 12, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the French National Authority for Health (“HAS”) released a favorable recommendation for the reimbursement of high-intensity focused ultrasound (HIFU) therapy in the treatment of prostate cancer. The... Read More
LYON, France, December 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors. Dr. Willsey replaces Dr. Argil Wheelock who has resigned as director of the Company. “I appreciate the opportunity to join the board of EDAP, where the company’s Focal One Robotic HIFU platform is... Read More
LYON, France, November 30, 2023 - EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that is has received the Industry Category Award from the French National Institute for Intellectual Property (INPI) based on the Company’s innovative therapeutic ultrasound technology. On November 23, 2023, the jury for the 2023 edition of the INPI Trophies honored five companies at an... Read More
LYON, France, November 20, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Piper Sandler 35 th Annual Healthcare Conference, which is being held November 28-30, 2023, in New York, New York. Presentation details: Date: Wednesday,... Read More
Strong Q3 2023 U.S. Focal One ® HIFU procedure growth of +150% year-over-year Record nine months HIFU revenues reflecting growing demand Two additional Focal One systems already placed in the fourth quarter Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology Company to host conference call and webcast today, Thursday, November 9 th at 8:30 am EDT LYON, France, November 9, 2023 -... Read More
LYON, France, November 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies London Healthcare Conference, which is being held November 14-16, 2023, in London. Presentation details: Date: Tuesday, November 14 Time: 9:00 – 9:25... Read More
Company to host conference call and webcast on Thursday, November 9 th at 8:30am EDT LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30 th , 2023, before the markets open on Thursday, November 9 th , 2023. An accompanying conference call and... Read More
LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the upcoming Morgan Stanley 21 st Annual Global Healthcare Conference and the H.C. Wainwright 25 th Annual Global Investment Conference, both being held September... Read More
Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD 31.5 million), respectively Total HIFU Q2 2023 year-over-year revenue growth of 63.6% Strong Q2 2023 year-over-year U.S. Focal One ® HIFU procedure growth of 85% Received reimbursement approval in Switzerland for use of HIFU in the treatment of prostate cancer More than half of patients now enrolled in Phase 3 study... Read More
Company to host conference call and webcast on Thursday, August 24 th at 8:30 am EDT LYON, France, August 10, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30 th , 2023, before the markets open on Thursday, August 24 th , 2023. An accompanying conference call and webcast will be hosted by... Read More
LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023. "Receipt of appropriate reimbursement from the Swiss healthcare authorities is... Read More
LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Healthcare Conference, which is being held June 7-9, 2023, in New York City. Presentation details: Date: Wednesday, June 7 Time: 1:30-1:55 PM ET in Track 2... Read More
Record first quarter revenue Positive results from two studies reconfirm safety and efficacy of Focal One Company to host conference call and webcast today, Wednesday, May 17 th at 8:30 am EDT LYON, France, May 17, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter ended March 31, 2023. “After achieving record results in... Read More
Company to host conference call and webcast on Wednesday, May 17 th at 8:30 am EDT LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31 st , 2023 before the markets open on Wednesday, May 17 th , 2023. An accompanying conference call and webcast will be hosted... Read More
Meeting to Showcase EDAP’s Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the Company will be showcasing its Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the... Read More
Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer Webcast scheduled for Tuesday, April 18 th at 12:00 p.m. PDT (3:00 p.m. EDT) LYON, France, April 10, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced that the Company will host a webcast that will feature a live procedure broadcast of its Focal One HIFU as a potential... Read More
Allows for market launch of the only micro-ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today provided a regulatory and clinical update. The Company has received approval from the Pharmaceutical and Medical Devices Agency (“PMDA”) for the commercialization of the ExactVu™ micro-ultrasound... Read More
Record full-year 2022 total revenue of EUR 55.1 million ($58.0 million) increased 25.1% over full-year 2021 Full-year HIFU revenue was EUR 15.6 million (USD 16.4 million), an increase of 57.7% as compared to EUR 9.9 million (USD 11.7 million) for the full-year 2021 Record Q4 2022 total revenue of EUR 15.7 million ($16.2 million) versus EUR 14.0 million ($15.9 million) for Q4 2021 Ended the year with a strong cash position of... Read More
Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP) The HIFU treated arm showed significant benefits across multiple side effect and quality-of-life measures LYON, France, March 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), a global leader in robotic energy-based therapies, today announced a... Read More
LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30 th , 2023. An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive... Read More
Record full-year 2022 total preliminary unaudited revenue of €55.1 million ($58.0 million) represents an increase of 25.1% over full-year 2021, driven by 58.1% HIFU growth Record Q4 2022 total preliminary unaudited revenue of €15.8 million ($16.2 million) versus €14.0 million ($15.9 million) for Q4 2021 Maintains strong balance sheet with cash and cash equivalents of €63.1 million ($67.5 million) as of December 31, 2022... Read More
Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL) Positive safety profile with 96.7% of patients with no or non-significant adverse events Data was presented at the Paris Santé Femmes Major Gynecology French Congress on Friday, January 27 Company intends to initiate randomized, double-blind, SHAM-controlled study in 2Q 2023 LYON, France, January 31, 2022 --... Read More
Company preliminarily reports nine Focal One Placements in the U.S., including seven sales LYON, France, January 5, 2023 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies, announced today that the Company experienced robust demand for its Focal One HIFU technology in the fourth quarter of 2022, placing nine Focal One machines in the U.S. The breadth of new placements also... Read More
Study to begin enrolling patients in Q2 2023 Endometriosis represents significant expansion opportunity for Focal One LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has received approval from French authorities to initiate a Phase 3 randomized, controlled clinical trial evaluating Focal One high intensity... Read More
Amneal Pharmaceuticals

COPYRIGHT ©2023 HEALTH STOCKS HUB